The University of Texas MD Anderson Cancer Center and Guardant Health have entered a multi-year research and development agreement to equip MD Anderson with integrated comprehensive liquid biopsy (CLB) capabilities. As an initial step in the partnership, Guardant Health’s Guardant360 CLB will become the preferred liquid biopsy at MD Anderson and MD Anderson physicians will be able to order it directly from the institution’s electronic medical record. Over the longer term, Guardant Health will help MD Anderson build multiple on-site liquid biopsy centers to enable development of novel assays using Guardant Health’s Digital Sequencing technology. The two institutions will jointly fund interventional clinical utility studies to demonstrate how CLB can improve patient outcomes across multiple types and stages of cancer. They will also work together on other clinical utility studies exploring how to incorporate CLB testing into national guidelines and drive its adoption as a national standard of care in cancer treatment.